Sequencing Abiraterone and Enzalutamide in mCRPC

February 20, 2014
Sumanta Kumar Pal, MD

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

  • This study is a retrospective analysis aiming to characterize the activity of abiraterone following enzalutamide and vice versa
  • Data sets like these are becoming increasingly important and speak to potential resistance that evolves when a patient receives one drug or the other for mCRPC
  • This study, as well as others, have shown that receiving one drug may compromise the efficacy of the second